Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of P1101 in Japanese PV and ET patients completing prior P1101 studies
jRCT2031200269Recruiting
- Sponsor
- PharmaEssentia
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV) and thrombocythemia (2 arms), sponsored by PharmaEssentia. Primary endpoints: Maintenance rate of phlebotomy-free complete hematologic response (CHR) in PV patients, Therapeutic effect and maintenance rate in ET patients by modified ELN criteria and 3 more. Started Jan 2021; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on jRCT2031200269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200269.